The ARDAT consortium – “Accelerating Research and Development for Advanced Therapies” is a collaboration between academic institutions (Universities and Research Centres), small and medium-sized businesses, and European Federation of Pharmaceutical Industries and Association (EFPIA) members, which is due to run until November 2025 and is funded by the Innovative Medicines Initiative (IMI).
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ardat.org/
- Keywords
- Gene Therapy and Cell Therapy.
- Competitors
- Pinnacle Biopartners, Innovation Hubs for Gene Therapies, ASPHALION, Aspire BioScience, PEPR Biothérapies et Bioproduction de Thérapies Innovantes, Innovation Hub for Gene Therapies: London (GTVF), EUROPEAN GENERIC MEDICINES ASSOCIATION, Native Labs, Carrigent, COAST CONNECT INTERNATIONAL HOLDINGS.
Accelerating Research & Development For Advanced Therapies (Ardat) Questions
Accelerating Research & Development For Advanced Therapies (Ardat)'s website is https://ardat.org/
Accelerating Research & Development For Advanced Therapies (Ardat)'s LinkedIn profile is https://www.linkedin.com/company/ardat
Accelerating Research & Development For Advanced Therapies (Ardat)'s industry is
Biotechnology Research
Accelerating Research & Development For Advanced Therapies (Ardat)'s top competitors are
Pinnacle Biopartners,
Innovation Hubs For Gene Therapies,
Asphalion,
Aspire Bioscience,
Pepr Biothérapies Et Bioproduction De Thérapies Innovantes,
Innovation Hub For Gene Therapies: London (Gtvf),
European Generic Medicines Association,
Native Labs,
Carrigent,
Coast Connect International Holdings.
Accelerating Research & Development For Advanced Therapies (Ardat)'s categories are Biotechnology Research
